PURE Bioscience Receives EPA Approval for Expanded Axen30 Claims; Powerful Axenohl-based Disinfectant Approved for Use in Childcare Facilities

***

Health/Medical Writers / Business Editors SAN DIEGO--(BUSINESS WIRE)--PURE-- PURE Bioscience (OTCBB:PURE) today announced it has received EPA approval to expand claims made for its Axen(R)30 hard surface disinfectant to include use on hard surfaces in childcare facilities. The EPA previously approved Axen30 for disinfection of hard surfaces including those in restaurants, homes and medical facilities. Michael L. Krall, president and CEO of PURE Bioscience, stated, "Expanded use claims for our Axen30 disinfectant now feature children's toys, toy boxes, play tables and activity centers, jungle gyms, playpens, child car seats, strollers and diaper changing tables. The EPA's approval of such sensitive use sites emphasizes the `least-toxic' characteristics of Axen30 while expanding its versatility in the professional and consumer disinfection markets." Krall continued, "The new claims open key market opportunities for us as our distributors position to penetrate the childcare segment which includes daycare centers, preschools, schools, gymnasiums and children's activity centers." 30 Second Bacterial Kill Time Sets New Industry Standard Axen30 is a 30-part per million (ppm) use-dilution formula of the company's patented new molecule, silver dihydrogen citrate (trade name Axenohl(R)). EPA approved claims for Axen30 include a 30 second kill time and a 24 hour residual kill on standard indicator bacteria, a two minute kill time on the resistant bacteria MRSE and VRE, a 10 minute kill time on fungi, a 30 second kill time on HIV Type I, and a 10 minute kill time on other viruses. Axen30 is distinguished from many of the leading commercial and consumer products because of its superior efficacy combined with its lower toxicity ratings. For example, leading brand household spray disinfectants declare a 10-minute disinfection time against three widespread disease-causing bacteria: Staph, Pseudomonas and Salmonella (Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 15442 and Salmonella choleraesuis ATCC 10708), whereas Axen30 claims a 30-second disinfection time on these same organisms -- 20 times faster than the claims made by the leading competitor. Furthermore, based on the EPA toxicity categorization of antimicrobial products ranging from Category I (high toxicity) down to Category IV, Axen30 is a Category IV antimicrobial for which precautionary labeling statements are normally not required. This compares with Category II warning statements for most leading brands of antimicrobial products. Accelerating into Healthcare and Pharmaceuticals In September 2003, PURE Bioscience and Therapeutics Inc. entered into a general Development and Licensing Agreement to establish a collaborative program for the development and commercialization of personal care and healthcare products using PURE's proprietary silver dihydrogen citrate technology. Under the terms of the agreement, Therapeutics funds and directs all development activities and FDA regulatory filings. As announced in May 2004, pursuant to the general Development and Licensing Agreement, PURE has issued to Therapeutics a Product Specific License for women's health products. Therapeutics is pursuing several potential SDC-based women's health products and has initiated work on a lead product for which they intend to pursue FDA approval. Therapeutics expects its development efforts will lead to the filing of Investigational New Drug (IND) with the US Food and Drug Administration (FDA). About PURE Bioscience PURE Bioscience (PURE) develops and markets technology-based products in the bioscience and water treatment sectors to provide non-toxic solutions to global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its Axenohl(R) antimicrobials and Triglycylboride(TM) pesticides, represent innovative advances in diverse markets. PURE is currently America's leader in pharmaceutical water purification with its Fillmaster(R) equipment, and the company has expanded into residential water treatment with its Nutripure(R) water filtration systems. PURE Bioscience has headquarters in El Cajon, Calif. (San Diego metropolitan area) and its common stock is listed on the OTC Bulletin Board under the symbol "PURE." Incorporated in 1992, PURE Bioscience was formerly named Innovative Medical Services. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the company's current and future products and services in the marketplace, the ability of the company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release. KEYWORD: CALIFORNIA INDUSTRY KEYWORD: CHEMICALS/PLASTICS PHARMACEUTICAL BIOTECHNOLOGY PRODUCT SOURCE: PURE Bioscience CONTACT INFORMATION: PURE Bioscience, San Diego Donna Singer, 619-596-8600 DSinger@imspure.com www.pure-bioscience.com

------------------
Due Da Due......But Be Quick About It!!!!!

Therapeutics Inc. Begins Development of First Group of FDA Regulated Products using PURE Bioscience's Axenohl Silver Dihydrogen Citrate Technology

***

Health/Medical Writers / Business Editors SAN DIEGO--(BUSINESS WIRE)--PURE-- PURE Bioscience Issues Product Specific Exclusive License to Therapeutics Incorporated for Women's Health Anti-Infective Products PURE Bioscience (OTCBB:PURE) today announced that Therapeutics Inc. has begun development of the first group of FDA regulated products using PURE's patented Axenohl(R) silver dihydrogen citrate (SDC) antimicrobial technology. Following months of evaluation of formulations and potential indications, the Therapeutics Inc. product development team has identified several potential SDC-based women's health products and initiated work on a lead product for which they intend to pursue FDA approval. Dan Piaquadio, M.D., president and CEO of Therapeutics Inc., stated, "Women's health is a large dynamic market with $4.5B annual U.S. sales and significant unmet needs. We chose to initially focus on women's healthcare products because SDC's broad spectrum antimicrobial qualities may support development of improved therapeutic options for this category. We expect our development efforts will lead to the filing of Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA)." Dr. Piaquadio continued, "In addition to SDC's broad spectrum of antimicrobial activity, its mode of action may confer a low potential to induce bacterial resistance, a concern with currently available anti-infective products. Furthermore, our research shows it should be possible to leverage the unique characteristics of the technology elsewhere; therefore, we are moving quickly to pursue additional applications in other healthcare segments, including pediatrics and dermatology." Michael L. Krall, president and CEO of PURE Bioscience, added, "As we execute our short- and mid-term business strategies for silver dihydrogen citrate in diverse markets, it gives us great confidence to know that Therapeutics is advancing our longer-term goal of achieving FDA approvals for silver dihydrogen citrate. We believe silver dihydrogen citrate has enormous potential as an active ingredient in prescription and personal care products, and we are excited about Therapeutics' marketing-minded approach to product development." In September 2003, PURE Bioscience and Therapeutics Inc. entered into a general development and licensing agreement to establish a collaborative program for the development and commercialization of personal care and healthcare products using PURE's proprietary silver dihydrogen citrate technology. Under the terms of the agreement, Therapeutics will fund and/or direct all development activities and FDA regulatory filings. Pursuant to the general development and licensing agreement, PURE has issued to Therapeutics a product specific license agreement in the women's health arena. PURE Bioscience's patented new molecule, silver dihydrogen citrate (trade name Axenohl(R)), is an electrolytically generated source of stabilized ionic silver that can serve as the basis for a broad range of products in diverse markets. Axenohl liquid is colorless, odorless, tasteless, non-caustic and formulates well with other compounds. Axenohl-based antimicrobial technology is distinguished from competitors in the marketplace because of its superior efficacy combined with reduced toxicity. PURE currently has Environmental Protection Agency (EPA) registration for its 2400-parts per million (ppm) technical grade concentrate as well as for its Axen and Axen-30(R) hard surface disinfectant products for commercial, industrial and consumer applications. The company plans to register several new products with the EPA this year. About Therapeutics Inc. Therapeutics Inc. of La Jolla, Calif., is a private, internationally-recognized research and development corporation dedicated to product success through integration of innovative clinical and regulatory strategies, trial design, product development and competitive marketplace analysis. Focusing on new technologies, with an emphasis in topical drug development, Therapeutics Inc. manages all aspects of product development from the "bench top" to the physician's office. Therapeutics Inc. applies the expertise of seasoned scientists and clinicians to create project specific development plans executed in a milestone-driven project management style. Visit www.therapeuticsinc.com for more information. About PURE Bioscience PURE Bioscience (PURE) develops and markets technology-based products in the bioscience and water treatment sectors to provide non-toxic solutions to global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its Axenohl(R) antimicrobials and Triglycylboride(TM) pesticides, represent innovative advances in diverse markets. PURE is currently America's leader in pharmaceutical water purification with its Fillmaster(R) equipment, and the company has expanded into residential water treatment with its Nutripure(R) water filtration systems. PURE Bioscience has headquarters in El Cajon, Calif. (San Diego metropolitan area) and its common stock is listed on the OTC Bulletin Board under the symbol "PURE." Incorporated in 1992, PURE Bioscience was formerly named Innovative Medical Services. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the company's current and future products and services in the marketplace, the ability of the company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release. For additional information on PURE Bioscience contact: KEYWORD: CALIFORNIA INDUSTRY KEYWORD: ENVIRONMENT BIOTECHNOLOGY GOVERNMENT SOURCE: PURE Bioscience CONTACT INFORMATION: PURE Bioscience, San Diego Donna Singer, 619-596-8600 DSinger@imspure.com www.pure-bioscience.com

------------------
Due Da Due......But Be Quick About It!!!!!